search
Back to results

Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months

Primary Purpose

Dysentery, Dysentery, Bacillary

Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine
S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine
Sponsored by
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Dysentery

Eligibility Criteria

3 Months - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • 3 months old and above healthy people.
  • Subject or legal representative who consent and has signed written informed consent.
  • Subject and parent/guardian who is able to comply with all study procedures.
  • Subject who did't receive blood products within 30 days ,immune with any live vaccine within 14 days and inactivated vaccine within 7 days before vaccination.
  • Axillary temperature ≤37.0 ℃.

Exclusion Criteria:

  • Febrile illness (temperature ≥ 38°C) in the 3 days.
  • Subject who are allergic to tetanus toxoid.
  • Allergic history after vaccination.
  • Immunodeficiency diseases patients who administered with immunosuppressive agents.
  • In pregnancy or lactation or pregnant women.
  • Subject who are suffering from serious chronic diseases, infectious diseases, active infection, cardiovascular disease,liver or kidney disease.
  • Subject who have symptoms such as diarrhea, abdominal pain, and pus and bloody stools in the past 3 days.
  • History of allergy,eclampsia, epilepsy,brain trauma,encephalopathy and mental disease or family disease.
  • Subject who diagnosis of thrombocytopenia or other history of coagulopathy may cause intramuscular contraindication.
  • Children with abnormal labor(pregnancy week<37w,>42w),birth weight (<2500g,>4000g), asphyxia rescue history,congenital malformations or developmental disorders(Only applicable to 3-5 months old group)
  • Blood routine, blood chemistry and urinalysis laboratory collection abnormalities and the severity of grade 2 and above before immunization.
  • Subject who plan to participate in or is in any other drug clinical trial.
  • Any condition that, in the judgment of investigator, may affect trial assessment.

Sites / Locations

  • Yizhou Center for Disease Control and Prevention

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

High dose Group

low dose Group

Arm Description

Received Vaccine: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,10μg/dose

Received Vaccine: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,5μg/dose

Outcomes

Primary Outcome Measures

Occurrence of adverse events during a 30 day follow-up period after each vaccination

Secondary Outcome Measures

Full Information

First Posted
June 7, 2018
Last Updated
October 15, 2018
Sponsor
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT03561181
Brief Title
Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months
Official Title
A Single-center, Open, Phase I Clinical Trial to Evaluate Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months
Study Type
Interventional

2. Study Status

Record Verification Date
October 2018
Overall Recruitment Status
Completed
Study Start Date
July 18, 2017 (Actual)
Primary Completion Date
January 28, 2018 (Actual)
Study Completion Date
February 8, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate safety of S.flexneriza-S.sonnei Bivalent Conjugate Vaccine in healthy volunteers aged above 3 Months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dysentery, Dysentery, Bacillary

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
180 (Actual)

8. Arms, Groups, and Interventions

Arm Title
High dose Group
Arm Type
Experimental
Arm Description
Received Vaccine: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,10μg/dose
Arm Title
low dose Group
Arm Type
Experimental
Arm Description
Received Vaccine: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,5μg/dose
Intervention Type
Biological
Intervention Name(s)
S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine
Intervention Description
Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
Intervention Type
Biological
Intervention Name(s)
S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine
Intervention Description
Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
Primary Outcome Measure Information:
Title
Occurrence of adverse events during a 30 day follow-up period after each vaccination
Time Frame
30 day after each vaccination

10. Eligibility

Sex
All
Minimum Age & Unit of Time
3 Months
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 3 months old and above healthy people. Subject or legal representative who consent and has signed written informed consent. Subject and parent/guardian who is able to comply with all study procedures. Subject who did't receive blood products within 30 days ,immune with any live vaccine within 14 days and inactivated vaccine within 7 days before vaccination. Axillary temperature ≤37.0 ℃. Exclusion Criteria: Febrile illness (temperature ≥ 38°C) in the 3 days. Subject who are allergic to tetanus toxoid. Allergic history after vaccination. Immunodeficiency diseases patients who administered with immunosuppressive agents. In pregnancy or lactation or pregnant women. Subject who are suffering from serious chronic diseases, infectious diseases, active infection, cardiovascular disease,liver or kidney disease. Subject who have symptoms such as diarrhea, abdominal pain, and pus and bloody stools in the past 3 days. History of allergy,eclampsia, epilepsy,brain trauma,encephalopathy and mental disease or family disease. Subject who diagnosis of thrombocytopenia or other history of coagulopathy may cause intramuscular contraindication. Children with abnormal labor(pregnancy week<37w,>42w),birth weight (<2500g,>4000g), asphyxia rescue history,congenital malformations or developmental disorders(Only applicable to 3-5 months old group) Blood routine, blood chemistry and urinalysis laboratory collection abnormalities and the severity of grade 2 and above before immunization. Subject who plan to participate in or is in any other drug clinical trial. Any condition that, in the judgment of investigator, may affect trial assessment.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Du lin, Master
Organizational Affiliation
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Official's Role
Study Chair
Facility Information:
Facility Name
Yizhou Center for Disease Control and Prevention
City
Yizhou
State/Province
Guangxi
ZIP/Postal Code
546300
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months

We'll reach out to this number within 24 hrs